Global Oncology Academy

The Gut Microbiome: An Evidence-Based Approach to Managing Recurrent C difficile Infection

ReachMD Healthcare Image

Tune in for expert insights on C difficile infection and the impact of gut dysbiosis on the development of recurrent disease.

Available credits: 0.75


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Explore this series of three modules on C difficile infection and the impact of gut dysbiosis on the development of recurrent disease with Dr. Colleen Kelly, Associate Professor of Medicine in the Division of Gastroenterology at Warren Alpert Medical School of Brown University in Providence, Rhode Island, and Andrea Banty, Nurse Practitioner of Gastroenterology at Cedars-Sinai IBD Center in Los Angeles.

  • Disclosure of Conflicts of Interest

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Colleen Kelly, MD, FACG, AGAF
    Associate Professor of Medicine
    Division of Gastroenterology
    Warren Alpert Medical School of Brown University
    Providence, Rhode Island

    Colleen Kelly, MD, FACG, AGAF: consultant/advisor/speaker: Sebela Pharmaceuticals.

    Contributing Author
    Andrea Banty, DNP, FNP
    Nurse Practitioner
    Cedars-Sinai IBD Center
    Los Angeles, California

    Andrea Banty, DNP, FNP, has no relevant financial relationships to disclose.

    The planners and content peer reviewers from Partners for Advancing Clinical Education, Practicing Clinicians Exchange, and American Gastroenterological Association do not have any relevant financial relationships to disclose.

  • Target Audience

    NPs and PAs who practice gastroenterology

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Review the impact of gut dysbiosis on the development of recurrent CDI
    • Apply evidence-based treatment strategies for patients with CDI based on guideline recommendations 
    • Detail the safety and efficacy for emerging standardized microbiota therapies for recurrent CDI
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    ANCC Credit Designation
    Nursing contact hours: The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours, including 0.75 hours of pharmacology credit. 

    AAPA Credit Designation
    Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until June 15, 2024. PAs should only claim credit commensurate with the extent of their participation.

    IPCE Credit Designation
    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Partners for Advancing Clinical Education (PACE)  in partnership with the American Gastroenterological Association (AGA).

  • Commercial Support

    This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free